Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 28, 2014; 20(8): 1993-2004
Published online Feb 28, 2014. doi: 10.3748/wjg.v20.i8.1993
Figure 1
Figure 1 Treatment sequences achieving best clinical outcomes in specified patient population based on current clinical data. Red circles show where biologic targets fit into the cytotoxic treatment sequence (shown in grey boxes) and the specific circumstances that favor its use (shown in dashed comments). Bev: Bevacizumab; Cet: Cetuximab; Pan: Panitumumab; Reg: Regorafenib; Afl: Aflibercept; Cape: Capecitabine; WT: Wild-type; RAS WT: wild-type KRAS and NRAS. 5-FU: 5-fluorouracil.